| Number | Percentage (%) |
---|---|---|
Gender | ||
 Male | 7 | 46.7 |
 Female | 8 | 53.3 |
Age, years | ||
 Median (range) | 58 (38–78) |  |
Primary tumor location | ||
 Esophagus | 3 | 20 |
 Pancreas | 1 | 6.7 |
 Cervix | 4 | 26.7 |
 Corpus uteri | 3 | 20 |
 Liver | 1 | 6.7 |
 Colon | 1 | 6.7 |
 Ureter | 1 | 6.7 |
 Cardia | 1 | 6.7 |
Pathological type | ||
 Squamous cell carcinoma | 7 | 46.7 |
 Adenocarcinoma | 2 | 13.3 |
 Hepatocellular carcinoma | 1 | 6.7 |
 Urothelium carcinoma | 1 | 6.7 |
 Endometrioid adenocarcinoma | 3 | 20 |
 Neuroendocrine carcinoma | 1 | 6.7 |
Previous treatment | ||
 EBRT | 15 |  |
 Prescribed doses (median, range) | 50.4 (30–80) |  |
Implantation location | ||
 Retroperitoneal lymph node | 13 | 76.5 |
 Adrenal gland | 3 | 17.6 |
 Pancreas | 1 | 5.9 |